Replies to post #192029 on Biotech Values

[Double_Bagel]

HALO helps by converting IV drugs to subcutaneous versions (Roche's Mabthera and Herceptin). Isn't Humira already administered subcutaneously? So, how would it help here? Thanks.

http://www.humirapro.com/Resources/HumiraPen.aspx

ABBV licenses HALO’s rHuPH20 technology for undisclosed products (of which one could be a new formulation of Humira):

[DewDiligence]

(HALO)—ABBV begins phase-1 trial of ENHANZE-enhanced Humira formulation:

http://finance.yahoo.com/news/halozyme-announces-first-clinical-dosing-133500254.html

This triggers a $5M milestone payment to HALO.